Eli Lilly and Company (LLY) key performance indicators and operating metrics (11 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Revenue (outside U.S.) | 6.4B | FY2025-Q4 |
| Revenue - U.S. | 12.9B | FY2025-Q4 |
| Revenue (total) | 19.3B | FY2025-Q4 |
| Revenue - Verzenio (worldwide) | 1.6B | FY2025-Q4 |
| Mounjaro revenue (worldwide) | 7.4B | FY2025-Q4 |
| Revenue (Zepbound - U.S.) | 4.2B | FY2025-Q4 |
| EPS (Non-GAAP) | 7.54 USD_per_share | FY2025-Q4 |
| Effective tax rate (GAAP) | 19.70 percent | FY2025-Q4 |
| Gross margin % (non-GAAP) | 14.71B | FY2025-Q3 |
| Effective tax rate | 22.80 percent | FY2025-Q3 |
| Total operating expense | 7.23B | FY2025-Q3 |
Back to LLY overview · LLY earnings · LLY holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.